Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States

Paschalis Vergidis, Raymund R. Razonable, L. Joseph Wheat, Lynn Estes, Angela M. Caliendo, Lindsey R. Baden, John R. Wingard, John Baddley, Maha Assi, Steven Norris, Pranatharthi Chandrasekar, Ryan Shields, Hong Nguyen, Alison Freifeld, Richard Kohler, Martin Kleiman, Thomas J. Walsh, Chadi A. Hage

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Piperacillin-tazobactam (PTZ) is known to cause false-positive results in the Platelia Aspergillus enzyme-linked immunoassay (EIA), due to contamination with galactomannan (GM). We tested 32 lots of PTZ and 27 serum specimens from patients receiving PTZ. GM was not detected in the lots of PTZ; one serum specimen (3.7%) wa.

Original languageEnglish (US)
Pages (from-to)2199-2201
Number of pages3
JournalJournal of clinical microbiology
Volume52
Issue number6
DOIs
StatePublished - Jun 2014

    Fingerprint

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Vergidis, P., Razonable, R. R., Wheat, L. J., Estes, L., Caliendo, A. M., Baden, L. R., Wingard, J. R., Baddley, J., Assi, M., Norris, S., Chandrasekar, P., Shields, R., Nguyen, H., Freifeld, A., Kohler, R., Kleiman, M., Walsh, T. J., & Hage, C. A. (2014). Reduction in false-positive aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. Journal of clinical microbiology, 52(6), 2199-2201. https://doi.org/10.1128/JCM.00285-14